These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38233256)

  • 1. The International Working Group on New Developments in Pharmacovigilance: Advancing Methods and Communication in Pharmacovigilance.
    Cooper D; Platt RW; van Hunsel F; Davies M; Yeomans A; Lane S; Shakir S
    Clin Ther; 2024 Jul; 46(7):565-569. PubMed ID: 38233256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
    Santoro A; Genov G; Spooner A; Raine J; Arlett P
    Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: protocol for a scoping review of the global literature.
    Sartori D; Aronson JK; Onakpoya IJ
    Syst Rev; 2020 Aug; 9(1):180. PubMed ID: 32791982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring Adverse Drug Events in Web Forums: Evaluation of a Pipeline and Use Case Study.
    Karapetiantz P; Audeh B; Redjdal A; Tiffet T; Bousquet C; Jaulent MC
    J Med Internet Res; 2024 Jun; 26():e46176. PubMed ID: 38888956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.
    Stergiopoulos S; Fehrle M; Caubel P; Tan L; Jebson L
    Pharmaceut Med; 2019 Dec; 33(6):499-510. PubMed ID: 31933240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection.
    Postigo R; Brosch S; Slattery J; van Haren A; Dogné JM; Kurz X; Candore G; Domergue F; Arlett P
    Drug Saf; 2018 Jul; 41(7):665-675. PubMed ID: 29520645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of medicines-Pharmacists' knowledge, practice, and attitudes toward pharmacovigilance and adverse drug reactions reporting process.
    Kopciuch D; Zaprutko T; Paczkowska A; Ratajczak P; Zielińska-Tomczak Ł; Kus K; Nowakowska E
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1543-1551. PubMed ID: 31148344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
    Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
    Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aims and approaches of Web-RADR: a consortium ensuring reliable ADR reporting via mobile devices and new insights from social media.
    Ghosh R; Lewis D
    Expert Opin Drug Saf; 2015; 14(12):1845-53. PubMed ID: 26436834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Patient's Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization.
    Smith MY; Benattia I
    Drug Saf; 2016 Sep; 39(9):779-85. PubMed ID: 27098248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knowledge Graphs in Pharmacovigilance: A Scoping Review.
    Hauben M; Rafi M; Abdelaziz I; Hassanzadeh O
    Clin Ther; 2024 Jul; 46(7):544-554. PubMed ID: 38981792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacovigilance in oncology: evaluation of current practice and future perspectives.
    Baldo P; De Paoli P
    J Eval Clin Pract; 2014 Oct; 20(5):559-69. PubMed ID: 24909067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacovigilance in China: development and challenges.
    Zhao Y; Wang T; Li G; Sun S
    Int J Clin Pharm; 2018 Aug; 40(4):823-831. PubMed ID: 30051225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to improve communication for the safe use of medicines?: Discussions on social marketing and patient-tailored approaches at the annual meetings of the WHO Programme for International Drug Monitoring.
    Bahri P; Harrison-Woolrych M
    Drug Saf; 2012 Dec; 35(12):1073-9. PubMed ID: 22974514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Navigating duplication in pharmacovigilance databases: a scoping review.
    Kiguba R; Isabirye G; Mayengo J; Owiny J; Tregunno P; Harrison K; Pirmohamed M; Ndagije HB
    BMJ Open; 2024 Apr; 14(4):e081990. PubMed ID: 38684275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of medicines and vaccines - building next generation capability.
    Bate A; Stegmann JU
    Trends Pharmacol Sci; 2021 Dec; 42(12):1051-1063. PubMed ID: 34635346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.